NewsRelease
ResearchArticle Cites HemogloBind™ in Parkinson’s Disease Study
MONMOUTHJUNCTION, NJ, January24, 2017 -- Biotech Support Group reports on a recent researcharticle describingthe simplicity and efficiency of their hemoglobin depletiontechnology for improving the signal from whole blood proteinimmunoblot analysis. The citation is:
Lahut,Suna, et al. "Blood RNA biomarkers in prodromal PARK4 and REMsleep behavior disorder show role of complexin-1 loss for risk ofParkinson's disease." DiseaseModels & Mechanisms(2017): dmm-028035.http://dmm.biologists.org/lookup/doi/10.1242/dmm.028035
Inthis study, Parkinson’s disease progression is investigatedthrough the accumulation and aggregation of the lipid-binding SNAREcomplex component alpha-synuclein (SNCA) which underliesvulnerability and defines its stages. The authors studied bloodsamples from a new large pedigree with SNCAgeneduplication (PARK4 mutation), to identify effects of SNCAgain-of-function as potential disease biomarkers. The article states“For protein extraction from the EDTA tubes, 300 μl bloodwere lysed with equal amount of 1% SDS-RIPA buffer [50 mM Tris-HCl(pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Igepal CA-630(Sigma), 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF and one tabletComplete Protease Inhibitor Cocktail (Roche)] and sonicated for 10sec. The blood lysates were rotated at 4 °C for 30 min andcentrifuged at 4 °C for 30 min. The supernatants were depleted inhemoglobin content using a commercial kit (HemogloBind, Biotech)following the manufacturer’s instructions”. Afterhemoglobin depletion, immunoblot analysis identified that PARK4 bloodshowed upregulation of alpha-synuclein monomer, with no highmolecular weight aggregates.
“Becauseof the large amount of hemoglobin in whole blood, its very excitingto see that HemogloBind™ can reduce the presence of hemoglobinsufficient for such precise immunoblot analysis.” states SwapanRoy, Ph.D., President and Founder of Biotech Support Group.
Formore information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866, [email protected]